I-Corps: Multiplex diagnostic assay using interdigitated nano-sensing technology implemented point-of-care device

I-Corps：使用叉指纳米传感技术实施的护理点设备进行多重诊断测定

• 批准号: 2318433
• 负责人: Eon Soo Lee
• 金额: $ 5万
• 依托单位: New Jersey Institute of Technology
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2318433&HistoricalAwards=false
• 关键词: Corps; Multiplex; diagnostic; assay; using

The broader impact/commercial potential of this I-Corps project is the development of the multiplex diagnostic assay and device using interdigitated nano-sensing technology for point-of-care diagnostics. The proposed initial application is the detection and monitoring of ovarian cancer. The early diagnosis of ovarian cancer is difficult because the benign condition usually obfuscates its symptoms. Currently, there are approximately 250,000 women living with ovarian cancer in the U.S., and ovarian cancer has more than a 70% chance to recur. The proposed technology may provide early detection of the ovarian cancer and monitoring functions to improve the survival rate and save thousands of women lives. In addition, the proposed diagnostic platform may be expanded to detect many other diseases, such as other cancers, malaria, and Covid-19, at commercial diagnostic laboratories. It is envisioned that the proposed technology may be used in hospitals and medical centers as well as physician's offices, pharmacies, and drug stores, which may make it more accessible and may save more lives and improve the quality of patients’ lives and health care environment.This I-Corps project is based on the development of a multiplex diagnostic assay and device using interdigitated nano-sensing technology for point-of-care diagnostics. The proposed technology is designed to separate biomolecules spontaneously in the microchannel of the device and detect multiplex biomarkers with high accuracy. The proposed technology initially will be used to test for ovarian cancer, and works by quantifying the concentrations of various biomarkers for ovarian cancer at an extremely low limit of detection (pico-level). It is a standalone device that consists of two main components: a microfluidic channel that is capable to separate the blood plasma spontaneously in the capillary blood flow, and a biosensing platform integrated with microchannels that contain multiple nano-biosensors used to detect various antigens at pico-level concentrations in the separated plasma. The proposed technology may be used to accurately test the concentration of targeted biomarkers and assist in the early diagnosis of cancer as well evaluate the efficacy of the treatment during the monitoring process.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目更广泛的影响/商业潜力是开发使用交叉指型纳米传感技术进行护理点诊断的多重诊断测定和设备。拟议的初步应用是检测和监测卵巢癌。 卵巢癌的早期诊断是困难的，因为良性状态通常会混淆其症状。目前，美国约有25万名女性患有卵巢癌，卵巢癌复发的机会超过70%。这项技术可以提供卵巢癌的早期检测和监测功能，以提高生存率并挽救数千名妇女的生命。 此外，拟议的诊断平台可能会扩展到在商业诊断实验室检测许多其他疾病，如其他癌症、疟疾和新冠肺炎。 设想所提出的技术可以用于医院和医疗中心以及医生办公室、药房和药店，这一I-Corps项目的基础是开发一种多重诊断测定法和装置，使用交叉指型纳米传感技术进行即时诊断。 所提出的技术被设计为在装置的微通道中自发地分离生物分子，并以高精度检测多重生物标志物。该技术最初将用于检测卵巢癌，并通过在极低的检测限（皮级）下定量卵巢癌的各种生物标志物的浓度来工作。它是一个独立的设备，由两个主要组件组成：一个微流体通道，能够在毛细血管血流中自发地分离血浆，和一个生物传感平台，与微通道集成，包含多个纳米生物传感器，用于检测分离血浆中皮级浓度的各种抗原。 该技术可用于准确检测靶向生物标志物的浓度，并有助于癌症的早期诊断，以及在监测过程中评估治疗效果。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

项目成果

Dean vortex-enhanced blood plasma separation in self-driven spiral microchannel flow with cross-flow microfilters

• DOI: 10.1063/5.0189413
• 发表时间: 2024-01-01
• 期刊: BIOMICROFLUIDICS
• 影响因子: 3.2
• 作者: Wang，Yudong;Talukder，Niladri;Lee，Eon Soo
• 通讯作者: Lee，Eon Soo